Traditionally, if you wanted prescription medication for weight loss, hair regrowth, or erectile dysfunction, you had to make an appointment with your doctor. Needless to say, that isn’t always a ...
The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a ...
The New England Patriots and the Seattle Seahawks may not be facing off at the Super Bowl until next weekend, but the ads that many tune in for have started rolling out. Telehealth startup Hims and ...
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans, driving 50% Y/Y revenue growth.
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate ...
By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, ...
In the last three months, 13 analysts have published ratings on Hims & Hers Health (NYSE:HIMS), offering a diverse range of ...
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is a trending stock: Facts to know before betting on it
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results